Robert B Chao, MD
1 year ago
Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF
Identified 7 ab in RD-ILD, emphasizing lack of autoimmunity in IPF
Different mechanisms of damage and progression based on ab profile?
@RheumNow #ACR23 Abs#2572 https://t.co/5rtXnOe9oJ
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis
-Anti-NT5c1A assoc with dysphagia
-Anti-Ro52/TRIM21: female
-Anti-VCP: male
-Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM
Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ
Aurelie Najm
1 year ago
Beware of the « HOT stuff 🌶️ bias »
In his very didactic catalogue of bias, Timothy McAlindon particularly warns us against the hot stuff, or the tendency to be less rigorous in the scientific approach when a topic is fashionable
@RheumNow #ACR23 https://t.co/rS8lItDrGS
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Abstr#2580 Could high-intensity resistance training improve outcomes in myositis? RCT showed 16 wks of training was tolerable, improved quality of life & functional capacity, without increasing disease activity/damage @RheumNow https://t.co/O1nP2x9C1L
Dr. John Cush RheumNow
1 year ago
#ACR23 BEST Abstracts from San Diego – Day 1
From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from 11/12/23. You can spot these on Twitter by looking for the (#ACRbest) hashtag.
https://t.co/h4RvFy66z9 https://t.co/LEhAUaw6Cj
Dr. John Cush RheumNow
1 year ago
Do Probiotics Improve PsA?
Probiotics and gut microbiome is a hot topic in the research world and amongst patients. Often, one the questions I get after sharing the diagnosis of PsA is, “Is there anything I can eat/not eat to make this better?” #ACR23
https://t.co/aK56UXz3gs https://t.co/p2AuzcWyq9
Dr. John Cush RheumNow
1 year ago
Who gives a ‘JAK’ why and how they work, as long as they do!
Several abstracts have studied the mechanism of action of JAKi in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. #ACR23
https://t.co/xqQF8SULgp https://t.co/DZtEly8GEq
Dr. John Cush RheumNow
1 year ago
RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: https://t.co/afJmqzzPYi
Dr. John Cush RheumNow
1 year ago
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23.
https://t.co/XvNMXAFkWe https://t.co/HVvBLhqe8H
These year’s annual ACR Convergence has been a success with the return of an insanely active Poster Hall! F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be.
Dr. John Cush RheumNow
1 year ago
#ACR23 Daily Recap Panel - Day 1
Join our live stream panel discussion as we dive deep into the highlights and key takeaways from day one of ACR 2023.
https://t.co/hApuycYzD2 https://t.co/1CD3rLLV7D
For as long as I can remember, methotrexate has been the anchor drug treatment of rheumatoid arthritis. We also know it has limited oral bioavailability at doses greater than 15mg. There are subcutaneous forms that offer better bioavailability, but its subcutaneous nature can sometimes sway patients away from trying it in addition to its higher cost. Split dosing of methotrexate can be a solution to attain higher bioavailability; however, its